摘要
老年性黄斑变性（AMD）的诊断治疗是国内外眼底病研究的热点，尤其是抗血管内皮细胞生长因子药物进入临床应用之后，不仅促进了AMD治疗研究的进展，同时也推动了AMD诊断和基础研究的进一步深入。多个国家和专业学会组织为此制订了临床指南，就AMD的流行病学特点、危险因素、诊断、分型以及诊疗过程进行了详细的阐述和规范性说明。这些内容多数基于现有较强的循证医学证据，对于AMD循证医学临床实践具有积极指导意义。学习借鉴这些经验，制订和建立具有中国特色的AMD治疗临床指南，规范和优化临床诊疗实践，提高治疗水平是我们必须面对而且亟待解决的问题。
The diagnosis and treatment of age-related macular degeneration （AMD） is an international hotspot of eye research. Successful clinical applications of anti-VEGF drugs promoted both basic research and clinical practice of AMD. A number of countries and professional societies have established clinical guidelines for AMD management, including the epidemiology, risk factors, diagnosis, classification, and treatment process. These AMD guidelines are mostly based on recently published results of clinical trials, provided good model of evidence based medicine. It is urgent and necessary to have our own guideline which is suitable for Chinese patients. Reviewing and learning existed guidelines will help us to improve the clinical practice of AMD in China.
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2012年第5期436-440,共5页
Chinese Journal of Ocular Fundus Diseases
基金
国家重点基础研究发展计划（2011CB707506）
国家自然科学基金（81100678）
上海市科委眼底病重点实验室开放课题（07222911）
关键词
黄斑变性/诊断
黄斑变性/治疗
脉络膜新生血管化/药物疗法
抗体
单克隆/治疗
应用
述评
Macular degeneration/diagnosis
Macular degeneration/therapy
Choroidal neovascularization/drug therapy
Antibodies, monoclonal/therapeutic use
Editorial
作者简介
通信作者：孙晓东，Email：xdsun@sjtu．edu．cn
